JAK1 and anemia (phenotype): As JAK2 inhibition is thought to be affiliated with the AEs of anemia seen in patients taking tofacitinib and baricitinib, likely due to JAK2′s role in erythropoiesis, it was suggested that upadacitinib’s purported JAK1-selectivity would reduce rates of anemia.